Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
Conditions: HER2-positive Breast Cancer; LMD Interventions: Drug: Tucatinib 150 MG; Drug: Trastuzumab; Drug: Capecitabine; Radiation: Brain & Spinal Radiation Sponsors: Sunnybrook Health Sciences Centre; Seagen Inc.; Viatris Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neurology | Research | Xeloda